Reviva Pharmaceuticals Holdings (RVPH) EBITDA (2018 - 2026)

Reviva Pharmaceuticals Holdings has disclosed EBITDA across 9 years of filings, most recently posting -$2.6 million for Q2 2026.

• In Q2 2026, EBITDA rose 56.9% year-over-year to -$2.6 million; the TTM figure through Jun 2026 stood at -$13.5 million (up 50.73% YoY), while the FY2025 annual figure was -$20.2 million, up 34.41% from the prior year.
• EBITDA came in at -$2.6 million for Q2 2026 at Reviva Pharmaceuticals Holdings, up from -$3.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$2.6 million in Q2 2026 to a low of -$11.6 million in Q3 2023.
• Average EBITDA over 5 years is -$6.9 million, with a median of -$6.8 million recorded in 2023.
• Year-over-year, EBITDA tumbled 297.95% in 2022 and jumped 56.9% in 2026.
• Over 5 years, EBITDA stood at -$8.9 million in 2022, then fell by 8.17% to -$9.6 million in 2023, then soared by 34.67% to -$6.3 million in 2024, then surged by 43.37% to -$3.6 million in 2025, then advanced by 26.45% to -$2.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$2.6 million in Q2 2026, -$3.3 million in Q1 2026, and -$3.6 million in Q4 2025.